Get the Stockscreener App
2.43
6.18%
-0.16
After Hours:
2.49
0.06
+2.47%
Clearmind Medicine Inc stock is traded at $2.43, with a volume of 85,334.
It is down -6.18% in the last 24 hours and down -66.82% over the past month.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
See More
Previous Close:
$2.59
Open:
$2.51
24h Volume:
85,334
Relative Volume:
0.25
Market Cap:
$3.64M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.0569
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
-7.25%
1M Performance:
-66.82%
6M Performance:
-93.17%
1Y Performance:
-95.02%
1-Day Range:
$2.42
$2.58
1-Week Range:
$2.4001
$2.8799
52-Week Range:
$2.36
$87.20
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
2.43 | 3.88M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.21 | 116.79B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.17 | 81.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.70 | 53.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
845.95 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.77 | 37.48B | 447.02M | -1.18B | -906.14M | -6.1812 |
Clearmind Medicine Inc Stock (CMND) Latest News
Trading Recap: How strong is Clearmind Medicine Inc. stock balance sheetJuly 2025 Selloffs & Weekly Setup with ROI Potential - moha.gov.vn
How interest rate cuts could boost Clearmind Medicine Inc. stock2025 Geopolitical Influence & Short-Term High Return Ideas - Улправда
Why retail traders accumulate Clearmind Medicine Inc. (CWY0) stockJuly 2025 PostEarnings & Reliable Breakout Forecasts - Улправда
Will Clearmind Medicine Inc. stock benefit from AI adoptionJuly 2025 Chart Watch & Comprehensive Market Scan Reports - Улправда
Why Clearmind Medicine Inc. stock remains on buy listsEarnings Trend Report & AI Powered Market Trend Analysis - DonanımHaber
Published on: 2025-12-19 05:54:25 - Улправда
Psychedelic: Clearmind completes second cohort enrollment for CMND-100 trial - TipRanks
Published on: 2025-12-18 16:01:28 - Улправда
Is Clearmind Medicine Inc. stock a top momentum playJuly 2025 Summary & Community Verified Trade Signals - Улправда
Sentiment Review: How Clearmind Medicine Inc CWY0 stock reacts to monetary easingJuly 2025 Setups & Weekly High Potential Alerts - moha.gov.vn
Clearmind Medicine completes second cohort enrollment in Phase I/IIa AUD trial - TipRanks
Clearmind Medicine announces successful completion of second cohort enrollment - marketscreener.com
Clearmind completes enrollment for second AUD treatment trial cohort - Investing.com
Clearmind completes enrollment for second AUD treatment trial cohort By Investing.com - Investing.com South Africa
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 - The Manila Times
Clearmind Medicine Inc. Announces Successful Enrollment of Second Patient Cohort in Phase I/IIa Trial for CMND-100 to Treat Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine (Nasdaq: CMND) fills 2nd CMND-100 AUD trial cohort - Stock Titan
Clearmind Medicine announces receipt of Nasdaq minimum bid price notification - MSN
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment - The Manila Times
Clearmind Medicine Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement - marketscreener.com
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - The Manila Times
Clearmind Medicine regains compliance with Nasdaq listing rule By Investing.com - Investing.com Canada
Clearmind regains compliance with Nasdaq minimum equity rule - Investing.com
Clearmind Medicine regains compliance with Nasdaq listing rule - Investing.com
Clearmind Medicine Inc. Regains Compliance with Nasdaq Listing Rule on Minimum Stockholders’ Equity - Quiver Quantitative
Clearmind regains compliance with Nasdaq minimum equity rule By Investing.com - Investing.com UK
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum ... | Associated Press | syndication news - Enidnews.com
Clearmind Medicine To Implement 1-for-40 Reverse Stock Split Next Week - Nasdaq
Why Did Clearmind Medicine Shares Plunge 29% After Hours? - Benzinga
Clearmind Medicine to enact 1-for-40 reverse share split; shares down - MSN
Clearmind Medicine to implement 1-for-40 reverse stock split - Investing.com India
Clearmind Medicine to implement 1-for-40 reverse stock split By Investing.com - Investing.com Australia
Clearmind Medicine Inc. Announces 1-for-40 Reverse Share Split to Regain Nasdaq Compliance - Quiver Quantitative
Clearmind Medicine Announces 1-for-40 Reverse Share Split - The Manila Times
Clearmind Medicine Announces 1-for-40 Reverse Share Split | Associated Press | syndication news - Enidnews.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification - marketscreener.com
Clearmind Medicine Shares Surge After Securing Final Approval for AUD Drug Trial Site - MSN
Clearmind Medicine reports regaining Nasdaq equity compliance after financings - Investing.com India
Clearmind Medicine reports regaining Nasdaq equity compliance after financings By Investing.com - Investing.com Australia
Clearmind Medicine Inc. Receives Nasdaq Compliance Notice Regarding Minimum Bid Price Requirement - Quiver Quantitative
Clearmind Medicine stock drops after Nasdaq compliance notice By Investing.com - Investing.com South Africa
Clearmind Medicine stock drops after Nasdaq compliance notice - Investing.com India
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):